Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 5,481,904 shares, a growth of 11.1% from the August 15th total of 4,933,164 shares. Currently, 3.5% of the company’s shares are short sold. Based on an average trading volume of 629,231 shares, the short-interest ratio is currently 8.7 days.

NAVB traded up $0.02 during trading hours on Wednesday, hitting $0.19. 1,213,958 shares of the company’s stock were exchanged, compared to its average volume of 310,170. Navidea Biopharmaceuticals has a 12-month low of $0.13 and a 12-month high of $0.68.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. Navidea Biopharmaceuticals had a negative return on equity of 38.60% and a negative net margin of 688.85%. The business had revenue of $0.54 million for the quarter.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Recommended Story: Leveraged Buyout (LBO) Explained

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply